ADALIMUMAB VERSUS INFLIXIMAB IN LUMINAL PEDIATRIC CROHN'S DISEASE: COMPARABLE OUTCOMES IN A PROSPECTIVE MULTICENTER COHORT STUDY.

Jennifer C deBruyn Hien Quoc Huynh Anne M Griffiths Kevan Jacobson David R MackColette DeslandresWael El-Matary Anthony R Otley Peter C Church Sally Lawrence Eytan Wine Mary Sherlock Jeffrey Critch Eric I Benchimol Prévost JantchouMohsin RashidMatthew W Carroll Kevin Bax Amanda RicciutoNicholas CarmanThomas D WaltersEileen Crowleynull null

Published in: The American journal of gastroenterology (2023)

Children with Crohn's disease achieved favourable outcomes at one year with either ADA or IFX as first antiTNF agents. Those receiving IFX did not have significantly superior outcomes compared to clinically similar children receiving ADA.

Keyphrases

young adults
rheumatoid arthritis
type diabetes